OPTIMIZATION OF TREATMENT OF PATIENTS WITH NON-ALCOHOLIC STEATOGEPATITIS COMBINED WITH DIABETES MELLITUS TYPE 2
Keywords:
non-alcoholic fatty liver disease, diabetes mellitus type 2, complex combined treatment.Abstract
The goal is to optimize the treatment of patients with non-alcoholic fat liver disease combined with type 2 diabetes. The study was conducted on 25 patients with NAFLD – in the stage of NASH. Control group – 20 healthy individuals. In order to identify the diagnosis of NAFLD, the data of clinical, laboratory, biochemical and instrumental studies were taken into account in full compliance with the standards of examination of patients with pathology of the organs of the gastrointestinal tract. Results and conclusions. In the application of integrated treatment with combined hypoglycaemic therapy (diabetes and pioglitazone), the results of treatment showed a significant improvement in the subjective and objective state of patients. Complaints have decreased significantly. Pain syndrome decreased by 1.4 times; dyspepsia syndrome – 1.7 times; decrease in appetite – in 1,7 times, astenovegetative syndrome – in 1,3 times; subcurrent sclera – 1.5 times; tongue bursts – 2 times; liver – in 1,3 times, pain of a liver at a palpation – in 1,4 times); densification of liver parenchyma – 1.5 times). During the ultrasound study in the group of NASH, the redistribution of the number of patients in the direction of reducing the heavier stages of hepatosis has taken place: the I stage is defined as 45% (increase 3 times), stage II - 35.0% (reduction by 1.4 times) , stage III - 20.0% (decrease by 1.75 times). In all patients the cytolysis, mesenchymal-inflammatory syndrome, hemograms improved, the indicators of protein and lipid metabolism were stabilized, confirming the positive lipidotrophic effect of the complex effect of diabetone and pioglitazone on the functional state of hepatocytes.
References
2. Dinnik N.V., Svintsitsky A.S., Solovyov G.A., Bogomaz V.M. Method of lifestyle modification in patients with nonalcoholic fatty liver disease. Practitioner 2016; 5 (No.): 6-8.
3. Mankovsky BN. Thiazolidinediones (glytazones) are a place in the treatment of patients with type 2 diabetes mellitus. Therapia Ukrainian Medical Bulletin. 2008,1: 22
4. Maruschak M.I., Antonichev M.M., Mazur L.P. Mechanisms of the formation of metabolic disorders in diabetic steatohepatitis. Modern gastroenterology. 2 (70): 30-34.
5. Unified clinical protocol of primary, secondary (specialized) medical aid. Non-alcoholic steatohepatitis / Order of the Ministry of Health of Ukraine November 06, 2014 No. 826.
6. Bril F., Cusi K. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am. Dec. 2016; 45 (4): 765-781.
7. Cernea S., Cahn A., Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol. 2017 May;10(5):535-547.
8. Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016 Jun;59(6):1112-20.
9. Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C. et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016 Sep 6;165(5):305-15.
10. Filipova E., Uzunova K., Kalinov K., Vekov T. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr. 2017 Nov 14;9:90.
11. Kawaguchi-Suzuki M., Bril F., Kalavalapalli S., Cusi K., Frye R.F. Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2017 Jul;46(1):56-61.
12. Lonardo A., Ballestri S., Marchesini G., Angulo P., Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015 Mar;47(3):181-90.
13. Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017 May 1;177(5):633-640.
14. Rizos C.V., Kei A., Elisaf M.S. The current role of thiazolidinediones in diabetes management. Arch Toxicol. 2016 Aug;90(8):1861-81.
15. Wang SL, Dong WB, Dong XL Zhu WM, Wang FF, Han F, Yan X, et al. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017 Aug 16;8(42):72700-72713.
